A detailed history of Virtu Financial LLC transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Virtu Financial LLC holds 12,861 shares of RARE stock, worth $425,441. This represents 0.02% of its overall portfolio holdings.

Number of Shares
12,861
Previous 11,817 8.83%
Holding current value
$425,441
Previous $430,000 10.0%
% of portfolio
0.02%
Previous 0.02%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

BUY
$26.31 - $41.44 $27,467 - $43,263
1,044 Added 8.83%
12,861 $387,000
Q2 2025

Aug 12, 2025

BUY
$31.06 - $39.3 $367,036 - $464,408
11,817 New
11,817 $430,000
Q1 2021

May 19, 2021

SELL
$106.9 - $167.73 $1.52 Million - $2.38 Million
-14,202 Closed
0 $0
Q4 2020

Feb 24, 2021

BUY
$84.4 - $177.39 $1.2 Million - $2.52 Million
14,202 New
14,202 $1.97 Million
Q2 2020

Aug 07, 2020

SELL
$46.91 - $78.22 $352,810 - $588,292
-7,521 Closed
0 $0
Q4 2019

Feb 04, 2020

BUY
$36.08 - $45.83 $271,357 - $344,687
7,521 New
7,521 $321,000
Q2 2019

Aug 13, 2019

SELL
$54.93 - $74.36 $342,158 - $463,188
-6,229 Closed
0 $0
Q1 2019

Apr 12, 2019

BUY
$39.87 - $69.36 $248,350 - $432,043
6,229 New
6,229 $432,000
Q4 2018

Jan 16, 2019

SELL
$38.89 - $77.3 $762,905 - $1.52 Million
-19,617 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$71.81 - $90.15 $1.41 Million - $1.77 Million
19,617 New
19,617 $1.5 Million
Q2 2018

Jul 30, 2018

SELL
$48.54 - $85.31 $179,355 - $315,220
-3,695 Closed
0 $0
Q2 2018

Jul 30, 2018

BUY
$48.54 - $85.31 $179,355 - $315,220
3,695 New
3,695 $284,000
Q1 2018

May 14, 2018

SELL
$44.33 - $58.52 $326,800 - $431,409
-7,372 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$43.54 - $57.32 $320,976 - $422,563
7,372
7,372 $342,000

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $2.32B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.